A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
Biosimilars
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
